Literature DB >> 10577988

The role of TNFalpha and lymphotoxin in demyelinating disease.

C Lock1, J Oksenberg, L Steinman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577988      PMCID： PMC1766588          DOI： 10.1136/ard.58.2008.i121

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  107 in total

1.  Array of hope.

Authors:  E S Lander
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

2.  Identification of autoantibodies associated with myelin damage in multiple sclerosis.

Authors:  C P Genain; B Cannella; S L Hauser; C S Raine
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

3.  Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis.

Authors:  R A Dal Canto; M K Shaw; G P Nolan; L Steinman; C G Fathman
Journal:  Clin Immunol       Date:  1999-01       Impact factor: 3.969

4.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

5.  Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque.

Authors:  C S Raine; B Bonetti; B Cannella
Journal:  Rev Neurol (Paris)       Date:  1998-09       Impact factor: 2.607

Review 6.  Glucocorticosteroid therapy for multiple sclerosis: a critical review.

Authors:  P B Andersson; D E Goodkin
Journal:  J Neurol Sci       Date:  1998-09-18       Impact factor: 3.181

7.  Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.

Authors:  D Leppert; J Ford; G Stabler; C Grygar; C Lienert; S Huber; K M Miller; S L Hauser; L Kappos
Journal:  Brain       Date:  1998-12       Impact factor: 13.501

8.  Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis.

Authors:  P Bongioanni; S Mosti; G Moscato; F Lombardo; C Manildo; G Meucci
Journal:  Arch Neurol       Date:  1999-01

9.  Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase.

Authors:  L W Myers; G W Ellison; J E Merrill; A El Hajjar; B St Pierre; M Hijazin; B D Leake; J R Bentson; M R Nuwer; W W Tourtellotte; P Davis; D Granger; J L Fahey
Journal:  Neurology       Date:  1998-11       Impact factor: 9.910

10.  Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

Authors:  A Miller; S Shapiro; R Gershtein; A Kinarty; H Rawashdeh; S Honigman; N Lahat
Journal:  J Neuroimmunol       Date:  1998-12-01       Impact factor: 3.478
View more
  13 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage.

Authors:  Makoto Inoue; Po-Han Chen; Stephen Siecinski; Qi-Jing Li; Chunlei Liu; Lawrence Steinman; Simon G Gregory; Eric Benner; Mari L Shinohara
Journal:  Nat Neurosci       Date:  2016-11-07       Impact factor: 24.884

3.  Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls.

Authors:  Andrea T White; Alan R Light; Ronald W Hughen; Timothy A Vanhaitsma; Kathleen C Light
Journal:  Psychosom Med       Date:  2011-12-30       Impact factor: 4.312

Review 4.  Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

Authors:  Ippazio Cosimo Antonazzo; Emanuel Raschi; Luca Vignatelli; Elisa Baldin; Trond Riise; Roberto D'Alessandro; Fabrizio De Ponti; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

5.  Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha.

Authors:  David Stellwagen; Eric C Beattie; Jae Y Seo; Robert C Malenka
Journal:  J Neurosci       Date:  2005-03-23       Impact factor: 6.167

6.  Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.

Authors:  Oliver Crespo; Stacey C Kang; Richard Daneman; Tamsin M Lindstrom; Peggy P Ho; Raymond A Sobel; Lawrence Steinman; William H Robinson
Journal:  J Clin Immunol       Date:  2011-08-17       Impact factor: 8.317

7.  Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis.

Authors:  Katerina Akassoglou; Ryan A Adams; Jan Bauer; Peter Mercado; Vivian Tseveleki; Hans Lassmann; Lesley Probert; Sidney Strickland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

8.  Cannabinoid receptor activation reduces TNFalpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity.

Authors:  Pingwei Zhao; Dmitri Leonoudakis; Mary E Abood; Eric C Beattie
Journal:  Neuropharmacology       Date:  2009-08-04       Impact factor: 5.250

9.  Cynical hostility and stimulated Th1 and Th2 cytokine production.

Authors:  Denise Janicki-Deverts; Sheldon Cohen; William J Doyle
Journal:  Brain Behav Immun       Date:  2009-07-30       Impact factor: 7.217

Review 10.  Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.

Authors:  Rosario Peluso; Giovanni Cafaro; Alessandro Di Minno; Salvatore Iervolino; Pasquale Ambrosino; Gelsy Lupoli; Matteo Nicola Dario Di Minno
Journal:  Clin Rheumatol       Date:  2013-04-16       Impact factor: 3.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.